Rixbase contains Rifaximin, a broad-spectrum antibiotic derived from rifamycin. It acts locally in the intestine to inhibit bacterial growth without significant absorption into the bloodstream. Rixbase is primarily used for treating hepatic encephalopathy, traveler’s diarrhea, and irritable bowel syndrome with diarrhea (IBS-D). It helps reduce harmful gut bacteria and toxins that affect liver and digestive health.

Mechanism of Action:
Rifaximin works by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting bacterial RNA synthesis. This action prevents the bacteria from growing and reproducing.

• In hepatic encephalopathy, it decreases ammonia-producing bacteria in the intestines, reducing toxin absorption into the bloodstream.

• In traveler’s diarrhea and IBS-D, it restores healthy gut flora balance and relieves gastrointestinal symptoms.

Uses:

• Hepatic encephalopathy (to lower recurrence risk)

• Traveler’s diarrhea caused by non-invasive E. coli

• Irritable Bowel Syndrome with diarrhea (IBS-D)

• Small intestinal bacterial overgrowth (SIBO) (off-label use)

Adverse Effects:
Rixbase is generally safe since it acts locally in the gut, but some mild side effects may occur:

• Nausea or abdominal pain

• Flatulence or bloating

• Headache or dizziness

• Constipation or diarrhea

• Fatigue

• Hypersensitivity reactions (rare) such as rash or itching